Evidence map›Paper›PMID 36892724›Full record

ArticleBreast cancer research and treatment2023

Treatment-related side effects among Hispanic and non-Hispanic white long-term breast cancer survivors by tamoxifen use and duration.

Kate E Dibble, Richard N Baumgartner, Stephanie D Boone, Kathy B Baumgartner, Avonne E Connor

Open access · greenAbstract read
In one paragraph

Article in Breast cancer research and treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Return to work or leaving work? Differences of return to work between breast cancer patients and the general population and determinants of return to work.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Observational
  2. Determinants of supportive care experiences for women living with breast cancer in rural communities of British Columbia.Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kate E DibbleDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD, USA. katee.dibble@dfci.harvard.edu.ORCID http://orcid.org/0000-0001-6791-2977
Richard N BaumgartnerDepartment of Epidemiology & Population Health, School of Public Health & Information Sciences, James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA.
Stephanie D BooneDepartment of Epidemiology & Population Health, School of Public Health & Information Sciences, James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA.
Kathy B Baumgartner *Department of Epidemiology & Population Health, School of Public Health & Information Sciences, James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA.
Avonne E Connor *Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD, USA.
University of Louisville · USJohns Hopkins University · US

Funding

INSTITUTIONAL RESEARCH CANCER EPIDEMIOLOGY FELLOWSHIPT32CA009314 · NCI · JOHNS HOPKINS UNIVERSITY · PI Corinne E. Joshu, Meghan Bridgid Moran · 1985 to 2026
$11.2M
Ethnicity, Breast Cancer Recurrence, & Long-Term QOLR01CA105266 · NCI · UNIVERSITY OF LOUISVILLE · PI BAUMGARTNER, KATHY B · 2005 to 2010
$1.6M
BREAST CANCER EPIDEMIOLOGY IN NM HISPANICSR01CA055730 · NCI · UNIVERSITY OF NEW MEXICO · PI GILLILAND, FRANK D. · 1991 to 1995
–
NCI NIH HHS R01 CA105266NCI NIH HHS R01-CA105266NCI NIH HHS R01-CA55730NCI NIH HHS T32 CA009314NCI NIH HHS T32CA009314Susan G. Komen KG090926
6 · The paper itself

Abstract

purposeTo determine the associations between ethnicity, age at diagnosis, obesity, multimorbidity, and odds of experiencing breast cancer (BC) treatment-related side effects among long-term Hispanic and non-Hispanic white (NHW) survivors from New Mexico and explore differences by tamoxifen use.

methodsLifestyle and clinical information including self-reported tamoxifen use and presence of treatment- related side effects were collected at follow-up interviews (12-15 years) for 194 BC survivors. Multivariable logistic regression models were used to examine associations between predictors and odds of experiencing side effects overall and by tamoxifen use.

resultsWomen ranged in age at diagnosis (30-74, M = 49.3, SD = 9.37), most were NHW (65.4%) and had in-situ or localized BC (63.4%). Less than half reportedly used tamoxifen (44.3%), of which 59.3% reported using > 5 years. Overall, survivors who were overweight/obese at follow-up were 5.42 times more likely to experience treatment-related pain (95% CI 1.40-21.0) compared to normal weight survivors. Survivors with multimorbidity, compared to survivors without, were more likely to report treatment-related sexual health issues (aOR 6.90, 95% CI 1.43-33.2) and poorer mental health (aOR 4.51, 95% CI 1.06-19.1). The statistical interactions between ethnicity and overweight/obese with tamoxifen use were significant (p-interaction < 0.05) for treatment-related sexual health issues.

conclusionOur results demonstrate that survivors with overweightness/obesity or multimorbidity may be more likely to experience BC treatment-related side effects. Tamoxifen use modifies associations between ethnicity, being overweight/obese, and sexual health issues following treatment. The likelihood of experiencing treatment-related side effects were more favorable for those on tamoxifen or those who had used tamoxifen for longer durations. These findings highlight the importance of fostering side effect awareness and applying appropriate interventions to assist with disease management throughout BC survivorship care.

Indexed as

Breast NeoplasmsCancer SurvivorsEthnicityFemaleHispanic or LatinoHumansNew MexicoObesityOverweightTamoxifenWhiteTamoxifenBreast cancerCancer survivorshipHispanic AmericansSide effectsTamoxifen

Identifiers

PMID36892724
PMCPMC10897699
OpenAlexW4323653179

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.